koto_feja
BODIES Bio (NASDAQ:TELA) announced on Thursday the commercial launch in the United States of Liquifix FIX8 and Liquifix Precision, FDA-approved surgical devices for mesh fixation of inguinal hernias.
While Liquifix FIX8 is approved for minimally invasive laparoscopic surgical repair of the femur and inguinal hernias, Liquifix Precision is indicated for open surgical repair.
“Aligned with our mission to prioritize the preservation and restoration of the patient's own anatomy, this novel device is a natural addition to our rapidly growing commercial portfolio,” said CEO Antony Koblish.
TELA's launch of Liquifix came a day after the company announced an agreement to sell distribution rights related to its wound care product, NIVIS Fibrillar Collagen Pack, to MiMedx Group (MDXG).
Under the terms, Georgia-based MiMedx (MDXG) agreed to pay $5 million upfront to TELA, plus $3 million to $7 million in future payments based on NIVIS net sales over the next two years. .
